X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1027) 1027
Publication (67) 67
Book Review (18) 18
Book Chapter (6) 6
Conference Proceeding (1) 1
Dissertation (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
glp-1 (640) 640
humans (512) 512
glucagon-like peptide-1 (485) 485
animals (480) 480
index medicus (448) 448
endocrinology & metabolism (422) 422
male (416) 416
glucagon (325) 325
glucagon-like peptide 1 (308) 308
diabetes (255) 255
insulin (254) 254
glucose (249) 249
rats (236) 236
type 2 diabetes (218) 218
female (217) 217
peptides (183) 183
diabetes mellitus, type 2 - drug therapy (177) 177
7-36 amide (170) 170
blood glucose - metabolism (161) 161
glucagon-like peptide-1 receptor (158) 158
secretion (155) 155
mice (154) 154
adult (149) 149
peptide fragments - pharmacology (148) 148
insulin - blood (147) 147
gastric-inhibitory polypeptide (145) 145
insulin - metabolism (141) 141
glucagon-like peptide 1 - metabolism (138) 138
middle aged (138) 138
incretin (137) 137
pharmacology & pharmacy (133) 133
obesity (128) 128
insulin secretion (125) 125
digestive, oral, and skin physiology (121) 121
research (117) 117
endocrine system (114) 114
physiological aspects (111) 111
medicine & public health (110) 110
glucagon-like peptides (107) 107
peptides - pharmacology (105) 105
exendin-4 (103) 103
biochemistry & molecular biology (102) 102
glucagon-like peptide 1 - pharmacology (101) 101
glp-1 receptor (99) 99
hypoglycemic agents - therapeutic use (99) 99
physiology (96) 96
insulin-secretion (95) 95
receptor (95) 95
hormones, hormone substitutes, and hormone antagonists (94) 94
internal medicine (94) 94
dextrose (92) 92
food-intake (92) 92
liraglutide (91) 91
expression (89) 89
gip (87) 87
analysis (86) 86
dependent insulinotropic polypeptide (85) 85
diabetes mellitus, type 2 - metabolism (85) 85
hypoglycemic agents - pharmacology (85) 85
diabetes mellitus, type 2 - blood (82) 82
glucagon - metabolism (81) 81
rats, wistar (81) 81
blood glucose - drug effects (80) 80
exenatide (79) 79
glucagon - blood (79) 79
rodents (79) 79
glucose metabolism (77) 77
health aspects (77) 77
type-2 diabetes-mellitus (77) 77
glycemic control (76) 76
pancreas (75) 75
glucose tolerance test (74) 74
glucagon-like peptide 1 - analogs & derivatives (73) 73
glucagon-like peptide 1 - blood (73) 73
diabetes mellitus (72) 72
peptide fragments - metabolism (71) 71
rats, sprague-dawley (71) 71
metabolism (70) 70
receptors, glucagon - metabolism (69) 69
aged (67) 67
glucagon - pharmacology (67) 67
glucose - metabolism (67) 67
amide (65) 65
beta-cell function (65) 65
healthy-subjects (65) 65
dose-response relationship, drug (62) 62
insulin resistance (62) 62
article (61) 61
care and treatment (60) 60
hyperglycemia (60) 60
medicine, research & experimental (60) 60
blood glucose - analysis (59) 59
diabetes-mellitus (59) 59
venoms - pharmacology (58) 58
in-vivo (56) 56
review (56) 56
time factors (56) 56
nutrition & dietetics (55) 55
dipeptidyl peptidase 4 - metabolism (54) 54
hormone (54) 54
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Chemico-Biological Interactions, ISSN 0009-2797, 04/2013, Volume 203, Issue 2, pp. 530 - 541
► We find out -glutamine increased glucagon like peptide-1. ► It increased mRNA expression for GLP-1. ► It improved glycemia, insulin release and active GLP-1... 
Docking | Antioxidant parameters | GLP-1 (7-36) amide | l-glutamine | Proglucagon gene expression | Insulin secretion | OXIDATIVE STRESS | L-glutamine | RECEPTOR AGONISTS | BIOCHEMISTRY & MOLECULAR BIOLOGY | GLIDE | CELL-PROLIFERATION | GLUCAGON-LIKE PEPTIDE-1 | ACCURATE DOCKING | GLUTATHIONE | PHARMACOLOGY & PHARMACY | TOXICOLOGY | STREPTOZOTOCIN | Triazoles - administration & dosage | Glycated Hemoglobin A - metabolism | Pyrazines - administration & dosage | Colon - drug effects | Body Weight - drug effects | Glutamine - metabolism | Glucagon-Like Peptide 1 - blood | Male | Pyrazines - metabolism | Insulin - blood | Glucagon-Like Peptide 1 - genetics | Glucagon-Like Peptide 1 - secretion | Diabetes Mellitus, Experimental - blood | Peptide Fragments - blood | Glutamine - pharmacology | Sitagliptin Phosphate | Diabetes Mellitus, Experimental - metabolism | Peptide Fragments - genetics | Diabetes Mellitus, Experimental - physiopathology | Glucose Tolerance Test | Peptide Fragments - metabolism | Glucagon-Like Peptide 1 - metabolism | Administration, Oral | Niacinamide - adverse effects | Peptide Fragments - secretion | Pancreas - drug effects | Pancreas - pathology | Rats | Receptors, Glucagon - metabolism | Pancreas - metabolism | Rats, Sprague-Dawley | Colon - metabolism | Gene Expression Regulation - drug effects | Triazoles - pharmacology | Triazoles - metabolism | Insulin - metabolism | Animals | Glucagon-Like Peptide-1 Receptor | Glutamine - administration & dosage | Lipid Metabolism - drug effects | Receptors, Glucagon - chemistry | Protein Conformation | Drinking - drug effects | Molecular Docking Simulation | Oxidative Stress - drug effects | Blood Glucose - metabolism | Pyrazines - pharmacology | Antioxidants | Niacinamide | Drugstores | Diabetes | Gene expression | Diabetes therapy | Glutamine
Journal Article
European Journal of Pharmacology, ISSN 0014-2999, 01/2013, Volume 698, Issue 1-3, pp. 470 - 479
In previous study, we have reported cycloart-23-ene-3β, 25-diol is an active antidiabetic constituent isolated from stem bark of (Linn.) Pierre. The objective... 
GLP-1 (7–36) amide | Oral glucose tolerance test | Antioxidant markers | Plasma glucose | Pancreatic β cells | mRNA proglucagon gene expression | Cycloart-23-ene-3β | 25-diol | Insulin | GLP-1 (7-36) amide | SYSTEM | Pancreatic beta cells | OXIDATIVE STRESS | PHYSIOLOGY | CELL-PROLIFERATION | PEPTIDE-1 RECEPTOR AGONISTS | DIPEPTIDYL PEPTIDASE-4 INHIBITORS | Cycloart-23-ene-3 beta | ACCURATE DOCKING | GLUTATHIONE | GLUCAGON-LIKE PEPTIDES | PHARMACOLOGY & PHARMACY | MICE | Triazoles - administration & dosage | Diabetes Mellitus, Experimental - drug therapy | Triterpenes - pharmacology | Pyrazines - administration & dosage | Triterpenes - therapeutic use | Body Weight - drug effects | Male | Pyrazines - metabolism | Pyrazines - therapeutic use | Insulin - blood | Glucagon-Like Peptide 1 - secretion | Diabetes Mellitus, Experimental - blood | Time Factors | Glucagon-Like Peptide 1 - agonists | Sitagliptin Phosphate | Diabetes Mellitus, Experimental - metabolism | Triterpenes - metabolism | Diabetes Mellitus, Experimental - physiopathology | Triazoles - therapeutic use | Biomarkers - metabolism | Glucose Tolerance Test | Peptide Fragments - metabolism | Glucagon-Like Peptide 1 - metabolism | Niacinamide - adverse effects | Peptide Fragments - secretion | Pancreas - drug effects | Rats | Glucagon-Like Peptide 1 - chemistry | Pancreas - metabolism | Rats, Sprague-Dawley | Gene Expression Regulation - drug effects | Triazoles - pharmacology | Triazoles - metabolism | Insulin - metabolism | Peptide Fragments - chemistry | Animals | Peptide Fragments - agonists | Protein Conformation | Drinking - drug effects | Molecular Docking Simulation | Oxidative Stress - drug effects | Blood Glucose - metabolism | Pyrazines - pharmacology | Triterpenes - administration & dosage
Journal Article
JOURNAL OF CLINICAL INVESTIGATION, ISSN 0021-9738, 04/1998, Volume 101, Issue 7, pp. 1421 - 1430
The gastrointestinal hormone, glucagon-like peptide-1(7-36)amide (GLP-1) is released after a meal, The potency of synthetic GLP-1 in stimulating insulin... 
MEDICINE, RESEARCH & EXPERIMENTAL | GLP-1 | insulin | RAT PANCREAS | INHIBITORY POLYPEPTIDE | entero-insulinar axis | PEPTIDE-1 7-36 AMIDE | PHYSIOLOGICAL INCRETIN | DIABETES-MELLITUS | FUNCTIONAL EXPRESSION | GENE-EXPRESSION | glucagon | GASTRIC-ACID SECRETION | INSULINOTROPIC POLYPEPTIDE RECEPTOR | CELL-LINE | exendin(9-39)amide
Journal Article
Journal of Neuroscience, ISSN 0270-6474, 02/2000, Volume 20, Issue 4, pp. 1616 - 1621
Journal Article
Journal Article
Diabetologia, ISSN 0012-186X, 11/1996, Volume 39, Issue 12, pp. 1546 - 1553
Intravenous glucagon-like peptide (GLP)-1 [7–36 amide] can normalize plasma glucose in non-insulin-dependent diabetic (NIDDM) patients. Since this is no form... 
36 amide | GLP-1 | Medicine & Public Health | Human Physiology | insulin | incretin | Metabolic Diseases | pharmacokinetics | Internal Medicine | glucagon | GLP-1 [7-36 amide] | HEALTHY-SUBJECTS | PANCREAS | DIABETES-MELLITUS | HORMONE | INJECTION | IN-VIVO | 7-36-AMIDE | ENDOCRINOLOGY & METABOLISM | DEGRADATION | GASTRIC-INHIBITORY POLYPEPTIDE | Gastrointestinal Hormones - pharmacokinetics | Glucagon-Like Peptide 1 | C-Peptide - blood | Humans | Middle Aged | Peptides - pharmacokinetics | Gastrointestinal Hormones - pharmacology | Male | Peptide Fragments - pharmacology | Insulin - blood | Glucagon - blood | Peptides - administration & dosage | Gastrointestinal Hormones - adverse effects | Glucagon-Like Peptides | Fasting - blood | C-Peptide - drug effects | Injections, Subcutaneous | Adult | Female | Fasting - metabolism | C-Peptide - metabolism | Peptide Fragments - administration & dosage | Peptide Fragments - pharmacokinetics | Glucagon - drug effects | Peptides - pharmacology | Gastrointestinal Hormones - administration & dosage | Diabetes Mellitus, Type 2 - blood | Insulin - metabolism | Diabetes Mellitus, Type 2 - physiopathology | Gastric Emptying - drug effects | Gastric Emptying - physiology | Glucagon - metabolism | Aged | Peptide Fragments - adverse effects | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Peptides - adverse effects | Cohort Studies
Journal Article